Factor VII TRIZ Cases
- Heterodimeric IgG1 pI Tuning for Homodimer Purification
Targeted constant-region pI shifts separate heterodimers from homodimers by ion exchange while helping extend antibody serum half-life.
- FVIII-VWF Chimeric Protein Architecture for Longer Half-Life
A chimeric FVIII-VWF protein uses a short XTEN linker and selected VWF domains to extend half-life and reduce dosing frequency in hemophilia A.
- AAV ATP7B Gene Therapy for Long-Term Wilson's Disease Correction
Liver-targeted AAV delivery of codon-optimized ATP7B lowers circulating copper and may provide lasting Wilson's disease correction.
- Chimeric FVIII-VWF Fragment Polypeptides for Extended Half-Life
A covalently linked FVIII and VWF fragment blocks endogenous VWF binding to extend FVIII half-life and reduce dosing frequency in hemophilia A.
- FVIII Variant Engineering for Lower Immunogenicity and Gene Delivery
Specific FVIII mutations such as N2118Q and B-domain deletion reduce immunogenicity while improving expression, secretion, and vector packaging.
- Heterodimeric IgG1 pI Engineering for Homodimer Purification
Charge-shifted IgG1 constant regions create pI gaps that separate heterodimers from homodimers and can also extend serum half-life.
- Modified Factor VIII Polypeptides for Lower-Dose Hemophilia A Gene Therapy
Specific Factor VIII amino acid substitutions boost secretion and clotting activity, enabling lower vector doses for hemophilia A treatment.
- Lentiviral Vector Formulation for Freeze-Thaw and Agitation Stability
A TRIS-free buffer with sucrose, surfactant, and salt helps lentiviral vectors resist freeze-thaw, agitation, and temperature stress.
- Single-Stranded AAV Vector Synthesis for Strand-Specific Purity
Cell-free synthesis from nicked closed-ended DNA enables strand-specific single-stranded AAV vectors with higher purity and expanded transgene capacity.
- Chimeric FVIII Purification Using Affinity and AEX Chromatography
A two-step affinity and anion exchange purification route improves chimeric FVIII purity and activity despite low expression and pH sensitivity.
- VWF-Binding Clotting Factor Chimeras for Longer Half-Life
Single-domain antibodies targeting the VWF D′D3 domain help clotting factor chimeras stay in circulation longer and reduce dosing frequency.
- Nuclease-Targeted IDLV for Precise Large-Sequence Integration
Engineered IDLVs use nuclease sites and homology arms to insert multi-kb sequences precisely with lower toxicity in stem cells.
- Liver-Targeted Lentiviral FVIII Vectors for Low-Dose Stable Expression
Codon-optimized liver-targeted lentiviral FVIII vectors enable stable hepatocyte integration and higher plasma activity at lower doses.
- ECM-Affinity Cytokine Conjugates for Tumor-Localized Cancer Therapy
ECM-binding peptides retain cytokines in tumor tissue, improving local therapeutic effect while limiting systemic toxicity and side effects.
- Heterodimeric IgG1 Charge Engineering for Homodimer Separation
Distinct constant-region pIs let charge-based methods separate IgG1 heterodimers from homodimers while supporting longer serum half-life.
- CALLAR T Cells for Sustained Elimination of Factor VIII Inhibitors
Genetically modified CALLAR T cells target B cells producing Factor VIII inhibitors to sustain titer reduction and lower bleeding risk.
- Cell-Specific FVIII Promoters for Low-Immunogenicity Gene Therapy
Cell-targeted promoter sequences sustain therapeutic FVIII expression while limiting immune responses and anti-FVIII antibodies in hemophilia A.